Loading patent…
AssigneesVanderbilt University, University of Washington
InventorsJeffrey T. Holt, Roy A. Jensen, Mary-Claire King, David L. Page, Csilla I. Szabo, Thomas L. Jetton, Cheryl L. Robinson-Benion, Marilyn E. Thompson
Estimating the term…
Genetic analysis of familial breast and ovarian cancer indicates that BRCA1 is a tumor suppressor gene. The BRCA1 gene encodes a 190 kDa protein with sequence homology and biochemical analogy to the granin family of proteins. Granins are secreted from endocrine cells via the regulated secretory pathway and are proteolytically cleaved to yield biologically active peptides. BRCA1 protein localizes to secretory vesicles, and was demonstrated to be secreted. Gene transfer of BRCA1 inhibits growth and tumorigenesis of breast and ovarian cancer cells, but not colon or lung cancer cells or fibroblasts, suggesting that BRCA1 encodes a tissue-specific growth inhibitor. Thus, BRCA1 is a secreted growth inhibitor and functions by a mechanism not previously described for tumor suppressor genes. The BRCA2 breast and ovarian cancer gene encodes a protein that also includes a granin region, indicating that the BRCA2 protein is also a secreted tumor suppressor. Therapeutic methods using the BRCA1 and BRCA proteins and genes are also described. A method of screening for the receptors of the BRCA1 protein and BRCA2 proteins is also described.
A method to suppress the growth of an epithelial ovarian tumor in a mammal, the method comprising introducing to an intraperitoneal cavity of the mammal at the site of said tumor a vector comprising a BRCA1 nucleic acid sequence encoding a BRCA1 protein having tumor suppressor activity, the nucleic acid sequence operatively linked to a promoter, wherein production of the BRCA1 protein results in a decrease in the growth rate of said epithelial ovarian tumor.
A method to reduce the growth of an epithelial ovarian tumor in a mammal, the method comprising injecting into the intraperitoneal cavity of said mammal, at the site of said epithelial ovarian tumor, an adenoviral construct comprising BRCA1 cDNA encoding a functionally active BRCA1 polypeptide operably linked to a promoter, wherein said BRCA1 polypeptide is expressed in said epithelial ovarian tumor at a level and for a period of time sufficient to reduce the growth of said epithelial ovarian tumor.
Dependencies are inferred from the claim text.